Atai Shares Rise on Beckley’s Psychedelic Drug Study Success

Atai Life Sciences NV shares climbed after a psychedelic nasal spray from Beckley Psytech Ltd, the company it plans to acquire, significantly eased depression symptoms in a mid-stage trial.

The study focused on patients with treatment-resistant depression who hadn’t responded to at least two prior antidepressants. A single dose of the drug, known as BPL-003, reduced symptoms within a day, with the effects lasting up to eight weeks, the two companies said in a statement.